C57BL/6-Cd3etm1(CD3E)Bcgen Cd3dtm1(CD3D)Bcgen Cd3gtm1(CD3G)Bcgen Cd19tm5(CD19)Bcgen Tnfrsf17tm2(TNFRSF17)Bcgen • 114828
Gene Information:
Protein Expression:
In vivo B-cell depletion by anti-human CD3/BCMA or anti-human CD3/CD19 bispecific antibodies (BsAbs) in B-hCD3EDG/hCD19/hBCMA mice. Bispecific antibodies (BMK1 and BMK2: targeting BCMA/CD3; BMK3: targeting CD19/CD3) or PBS control were administered as a single dose to B-hCD3EDG/hCD19/hBCMA mice (n=3 per group). Blood cells were harvested on day 1 and day 7 post-treatment. The frequency and absolute numbers of mCD45⁺ cells, B cells, and T cells were quantified by flow cytometry. Data are presented as mean ± SEM and analyzed by one-way ANOVA followed by Dunnett’s multiple comparisons test versus the PBS control group (*p<0.05, **p<0.01, ***p<0.001,****p<0.0001). This study was conducted in collaboration with our partner.
In vivo B-cell depletion by anti-human CD3/BCMA or anti-human CD3/CD19 bispecific antibodies (BsAbs) in B-hCD3EDG/hCD19/hBCMA mice. Bispecific antibodies (BMK1 and BMK2: targeting BCMA/CD3; BMK3: targeting CD19/CD3) or PBS control were administered as a single dose to B-hCD3EDG/hCD19/hBCMA mice (n=3 per group). Spleens were harvested on day 7 post-treatment. The frequency and absolute numbers of mCD45⁺ cells, B cells, T cells, plasma cells, and plasmablasts were quantified by flow cytometry. Data are presented as mean ± SEM and analyzed by one-way ANOVA followed by Dunnett’s multiple comparisons test versus the PBS control group (*p<0.05, **p<0.01, ***p<0.001,****p<0.0001). This study was conducted in collaboration with our partner.